

Supplementary table 1. Comparison of OSNA assessment results depending on distribution of demographic and clinical variables.

Variable	OSNA negative (n=57)	OSNA positive (n=25)	<i>p</i>
Sex Men Women	29 (65.9%) 28 (73.7%)	15 (34.1%) 10 (26.3%)	0,6016
Age <65 years ≥65 years	28 (68.3%) 29 (70.7%)	13 (31.7%) 12 (29.3%)	1.0000
Lauren`s type Intestinal Mixed Diffuse Unknown	26 (74.3%) 10 (62.5%) 14 (63.6%) 9 (%)	9 (25.7%) 6 (37.5%) 8 (36.4%) -	0.1671
(y)pT 0 1 2 3 4a 4b	7 (100%) 9 (75%) 8 (72.7%) 17 (58.6%) 13 (86.7%) 2 (28.6%)	- 3 (25%) 3 (27.3%) 12 (41.4%) 2 (13.3%) 5 (71.4%)	0.0292*
(y)pN 0 1 2 3a 3b	27 (73%) 11 (84.6%) 9 (75%) 8 (53.3%) 2 (40%)	10 (27%) 2 (15.4%) 3 (25%) 7 (46.7%) 3 (60%)	0.2238
(y)pM 0 1	54 (76.1%) 3 (27.3%)	17 (23.9%) 8 (72.7%)	0.0035*
(y)pTNM stage 0 IA IB IIA IIB IIIA IIIB IIIC IV	8 (100%) 9 (75%) 4 (66.7%) 5 (50%) 11 (91.7%) 4 (66.7%) 9 (81.8%) 4 (66.7%) 3 (27.3%)	- 3 (25%) 2 (33.3%) 5 (50%) 1 (8.3%) 2 (33.3%) 2 (18.2%) 2 (33.3%) 8 (72.7%)	0.0186*
Noadjuvant chemotherapy Yes No	42 (67.7%) 15 (75%)	20 (32.3%) 5 (25%)	0.7385
Tumour Regression Grade 1 2 3 4	6 (100%) 9 (60%) 18 (72%) 9 (60%)	- 6 (40%) 7 (28%) 6 (40%)	0.2614

Type of gastrectomy	11 (78.6%)	3 (21.4%)	0.4943
Proximal	26 (72.2%)	10 (27.8%)	
Distal	20 (62.5%)	12 (37.5%)	
Total			
Cytology			0.1238
positive	2 (33.3%)	4 (66.7%)	
negative	55 (72.4%)	21 (27.6%)	

Abbreviations: (y)pT – (postneoadjuvant) pathological primary tumour stage, (y)pN - (postneoadjuvant) pathological nodal stage, (y)pM - (postneoadjuvant) pathological distant metastasis stage, (y)pTNM - (postneoadjuvant) pathological tumour, node, metastasis, OSNA - One-Step Nucleic Acid Amplification Assay; * - statistically significant results.